Last reviewed · How we verify
Bimatoprost 0.01%
Bimatoprost 0.01% is a Prostaglandin F analog Small molecule drug developed by Allergan. It is currently FDA-approved for Open-angle glaucoma, Ocular hypertension, Hypotrichosis of the eyelashes (eyelash growth). Also known as: LUMIGAN® RC, LUMIGAN® 0.01%, Lumigan 0.01%, Lumigan® RC.
Bimatoprost is a prostaglandin F analog that binds to prostaglandin F receptors to increase uveoscleral outflow of aqueous humor, thereby reducing intraocular pressure.
Bimatoprost is a prostaglandin F analog that binds to prostaglandin F receptors to increase uveoscleral outflow of aqueous humor, thereby reducing intraocular pressure. Used for Open-angle glaucoma, Ocular hypertension, Hypotrichosis of the eyelashes (eyelash growth).
At a glance
| Generic name | Bimatoprost 0.01% |
|---|---|
| Also known as | LUMIGAN® RC, LUMIGAN® 0.01%, Lumigan 0.01%, Lumigan® RC, Lumigan® |
| Sponsor | Allergan |
| Drug class | Prostaglandin F analog |
| Target | Prostaglandin F receptor (FP receptor) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Bimatoprost mimics the action of prostaglandin F by activating F-prostanoid receptors in the eye. This activation enhances drainage of fluid (aqueous humor) through the uveoscleral pathway, the primary drainage route in the eye. The resulting decrease in intraocular pressure helps prevent optic nerve damage and vision loss in glaucoma and ocular hypertension.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
- Hypotrichosis of the eyelashes (eyelash growth)
Common side effects
- Conjunctival hyperemia (eye redness)
- Iris hyperpigmentation (darkening)
- Eyelid skin hyperpigmentation
- Eye irritation/discomfort
- Foreign body sensation
Key clinical trials
- AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension (PHASE1, PHASE2)
- A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes (PHASE1)
- Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients (PHASE3)
- Systemic Pharmacokinetic Study of T4032 (Unpreserved Bimatoprost 0.01%) Eye Gel Versus Lumigan® 0.01% Eye Drops in 40 Healthy Volunteers (PHASE1)
- A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension (PHASE3)
- Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% to LUMIGAN® In The Treatment of Chronic Open-Angle Glaucoma (PHASE3)
- Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes. (PHASE3)
- A Comparative Study of SPARC's SDP-133 Once Daily and Lumigan in Subjects With Open Angle Glaucoma or Ocular Hypertension (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bimatoprost 0.01% CI brief — competitive landscape report
- Bimatoprost 0.01% updates RSS · CI watch RSS
- Allergan portfolio CI
Frequently asked questions about Bimatoprost 0.01%
What is Bimatoprost 0.01%?
How does Bimatoprost 0.01% work?
What is Bimatoprost 0.01% used for?
Who makes Bimatoprost 0.01%?
Is Bimatoprost 0.01% also known as anything else?
What drug class is Bimatoprost 0.01% in?
What development phase is Bimatoprost 0.01% in?
What are the side effects of Bimatoprost 0.01%?
What does Bimatoprost 0.01% target?
Related
- Drug class: All Prostaglandin F analog drugs
- Target: All drugs targeting Prostaglandin F receptor (FP receptor)
- Manufacturer: Allergan — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Open-angle glaucoma
- Indication: Drugs for Ocular hypertension
- Indication: Drugs for Hypotrichosis of the eyelashes (eyelash growth)
- Also known as: LUMIGAN® RC, LUMIGAN® 0.01%, Lumigan 0.01%, Lumigan® RC, Lumigan®
- Compare: Bimatoprost 0.01% vs similar drugs
- Pricing: Bimatoprost 0.01% cost, discount & access